EMA Authorised: Odefsey (emtricitabine;rilpivirine hydrochloride;tenofovir alafenamide) — Gilead Sciences Ireland UC

View source ↗

Summary

EMA has authorised Odefsey (emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide) for HIV infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• ODEFSEY (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Gilead Sciences Ireland UC. Decision date: 16/02/2023